Stroke risk and NSAIDs: A systematic review of observational studies

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 12, 2011, Pages 1225-1236

  Varas Lorenzo, Cristina ^a   Riera Guardia, Nuria ^a   Calingaert, Brian ^a   Castellsague, Jordi ^a   Pariente, Antoine ^b   Scotti, Lorenza ^c   Sturkenboom, Miriam ^d   Perez Gutthann, Susana ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti inflammatory agents; Epidemiology; Meta analysis; Nonsteroidal; Observational studies; Stroke

Indexed keywords

CELECOXIB; DICLOFENAC; IBUPROFEN; NAPROXEN; ROFECOXIB;

BRAIN ISCHEMIA; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; STROKE; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RISK; STROKE; TIME FACTORS;

EID: 81955164820     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2227     Document Type: Review

References (31)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528, 1522 p following 1528.
2. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102. DOI: 10.1056/NEJMoa050493
3. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080. DOI: 10.1056/NEJMoa050405
4. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 1481-1492.
5. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006; 1: e33. DOI: 10.1371/journal.pctr.0010033
6. Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98: 266-274. DOI: 10.1111/j.1742-7843.2006.pto-302.x
7. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-1308. DOI: 10.1136/bmj.332.7553.1302
8. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644. DOI: 10.1001/jama.296.13.jrv60011
9. Scott PA, Kingsley GH, Smith CM, et al. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 2007; 66: 1296-1304. DOI: 10.1136/ard.2006.068650
10. Capone ML, Tacconelli S, Rodriguez LG, et al. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. Pharmacol Rep 2010; 62: 530-535.
11. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004; 109: 1468-1471. DOI: 10.1161/01.CIR.0000124715.27937.78
12. Abraham NS, El-Serag HB, Hartman C, et al. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 2007; 25: 913-924. DOI: 10.1111/j.1365-2036.2007.03292.x
13. Andersohn F, Schade R, Suissa S, et al. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 2006; 37: 1725-1730. DOI: 10.1161/01.STR.0000226642.55207.94
14. Bak S, Andersen M, Tsiropoulos I, et al. Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study. Stroke 2003; 34: 379-386.
15. Haag MD, Bos MJ, Hofman A, et al. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 2008; 168: 1219-1224. DOI: 10.1001/archinte.168.11.1219
16. Huang WF, Hsiao FY, Tsai YW, et al. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. Drug Saf 2006; 29: 261-272.
17. Huang WF, Hsiao FY, Wen YW, et al. Cardiovascular events associated using four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. Clin Ther 2006; 28: 1827-1836. DOI: 10.1016/j.clinthera.2006.11.009
18. Roumie CL, Mitchel EF, Jr., Kaltenbach L, et al. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 2008; 39: 2037-2045. DOI: 10.1161/STROKEAHA.107.508549
19. Solomon DH, Avorn J, Stürmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006; 54: 1378-1389. DOI: 10.1002/art.21887
20. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quailty of nonrandomised studies in meta-analyses. Ottawa, Ontario: Ottawa Health Research Institute 2010. Available at: Accessed Mar 17, 2010.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
22. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086. DOI: 10.1136/bmj.c7086
23. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
24. Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects--advantages and disadvantages. Nat Clin Pract Rheumatol 2007; 3: 725-732. DOI: 10.1038/ncprheum0652
25. Greenland S. Introduction to regression models. Hagerstown, MD: Lippincott-Raven; 1998.
26. Roumie CL, Mitchel E, Gideon PS, et al. Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data. Pharmacoepidemiol Drug Saf 2008; 17: 20-26. DOI: 10.1002/pds.1518
27. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 52: 1628-1636. DOI: 10.1016/j.jacc.2008.08.041
28. Mangoni AA, Woodman RJ, Gilbert AL, et al. Use of non-steroidal anti-inflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community. Pharmacoepidemiol Drug Saf 2010. DOI: 10.1002/pds.1945
29. Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res 2009; 18(1): 67-80. DOI: 10.1177/0962280208092347
30. Horwitz RI, Feinstein AR. Exclusion bias and the false relationship of reserpine and breast cancer. Arch Intern Med 1985; 145: 1873-1875.
31. Schürks M, Rist PM, Bigal ME, et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009; 339: b3914.